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WHAT THIS PAPER ADDS 
§ Emissions from vapourised nicotine products (VNP) including e-cigarettes contain 
carcinogens but generally in lower concentrations than tobacco smoke. 
§ Each carcinogen contributes quantifiably to the overall cancer potency and risk 
§ Users and policy makers need quantitative evidence on the relative risks of cancer from the 
use of VNPs compared with smoking tobacco. 
§ Previous studies considered the individual carcinogens in an emission; here a method is 
developed that models the aggregate cancer potencies of all carcinogens and overcomes 
incompatibilities in data reporting conventions for direct comparison of the potencies and 
risks of tobacco smoke with VNP emissions. 
§ Cancer potencies span five orders of magnitude creating a spectrum ranging from 
uncontaminated air through VNPs to tobacco smoke. 
§ Most e-cigarette analyses indicate cancer potencies <1% that of tobacco smoke and <10% 
that of a heat-not-burn prototype although a minority of analyses indicate higher potencies. 
§ Highly carcinogenic emissions from e-cigarettes are avoidable, being due largely to user 
choice of device setting, liquid formulation and vaping behaviour, highlighting a need for 
increased user awareness and personal involvement in reducing risk. 
ABSTRACT 
Background: Quantifying relative harm caused by inhaling the aerosol emissions of vapourised 
nicotine products compared with smoking combustible tobacco is an important issue for public 
health.  
Methods: The cancer potencies of various nicotine-delivering aerosols are modelled using 
published chemical analyses of emissions and their associated inhalation unit risks. Potencies are 
compared using a conversion procedure for expressing smoke and e-cigarette vapours in common 
units. Lifetime cancer risks are calculated from potencies using daily consumption estimates.  
Results: The aerosols form a spectrum of cancer potencies spanning five orders of magnitude from 
uncontaminated air to tobacco smoke. E-cigarette emissions span most of this range with the 
preponderance of products having potencies <1% of tobacco smoke and falling within two orders of 
magnitude of a medicinal nicotine inhaler, however a small minority have much higher potencies. 
These high-risk results tend to be associated with high levels of carbonyls generated when 
excessive power is delivered to the atomiser coil. Samples of a prototype heat-not-burn device have 
lower cancer potencies than tobacco smoke by at least one order of magnitude, but higher potencies 
than most e-cigarettes.  Mean lifetime risks decline in the sequence: combustible cigarettes ≫ heat-
not-burn ≫ e-cigarettes (normal power) ≥ nicotine inhaler.  
Conclusions: Optimal combinations of device settings, liquid formulation and vaping behaviour 
normally result in e-cigarette emissions with much less carcinogenic potency than tobacco smoke, 
notwithstanding there are circumstances in which the cancer risks of e-cigarette emissions can 
escalate, sometimes very substantially. These circumstances are usually avoidable when the causes 
are known. 
 
INTRODUCTION 
Opinion is divided about vapourised nicotine products (VNPs), such as e-cigarettes (ECs) which 
heat a nicotine-containing liquid and Heat-not-Burn (HnB) products which heat tobacco.[1, 2] The 
general public tends to view “vaping” ECs as equally or more harmful than smoking tobacco.[3, 4] 
More scientific evidence addressing the factors that lead to harm and, where possible, quantification 
of their effects is needed to inform scientific debates and address public uncertainty.[5]  
Both cigarette smoke and VNP emissions (or “vapour”) are aerosol mixtures of particulates and 
droplets in gaseous matrices`, but each is generated by a different process from different precursors 
within different temperature ranges. Nicotine is not a carcinogen but VNPs transfer a burden of 
known carcinogens in the aerosol. Assessing the relative harmfulness of different VNPs requires 
meaningful indicators of harm. Common approaches include the analysis of biomarkers in bodily 
fluids, in vivo and in vitro toxicity studies, and evaluating the numbers of individual chemicals that 
exceed a specified threshold of safety.[6-10] The health risks of smoking were established half a 
century ago by epidemiological evidence of associated morbidity and mortality but it may be 
several years before such approaches can definitively assess the harm of VNPs.[11] Meanwhile, 
public health advice depends on quantitative chemical and toxicological approaches to model VNP 
risks.  
This study aims to 1) derive a procedure that overcomes the problem of incompatible emissions 
datasets; 2) reduce the information on carcinogenic risk represented by multiple individual 
compounds to a single latent variable (potency) that reflects the cancer risk; and 3) calculate cancer 
potencies from published emissions data and compare various nicotine product risks by factoring in 
exposure estimates.  
METHODOLOGY 
Smoke and vapour emissions 
Compounds from mainstream smoke analyses are typically reported in mass units (mg, µg, ng as 
appropriate) per cigarette. Fewer analyses of hazardous compounds in VNPs have been published 
and the units reported vary widely, usually as mass of compound per volume of vapour (often as µg 
per N puffs where N ranges from 1 to several hundred puffs of fixed volume). A few studies report 
mass units of toxicant/volume of precursor e-liquid but these are not included in this study. 
Different machine smoking protocols purported to simulate human smoking adds another 
complication. The ISO protocol draws 35 mL per puff of smoke whereas the MDPH protocol draws 
45 mL and the HCI (intense) protocol draws 55 mL (see Supplementary file).[12] Only volume is 
considered here, not the withdrawal rate or interval between puffs. The ISO protocol leaves 
cigarette filter ventilation holes unblocked whereas MDPH blocks 50% by taping over half the filter 
circumference, and HCI blocks these holes entirely. Ventilation blocking reduces dilution by air and 
increases emissions, thus smoking protocol and filter ventilation are fundamental considerations 
when comparing toxicant concentrations in tobacco smoke with vapour.[13] 
Smoke toxicants conversion 
Taking ! to be the number of puffs in a smoking experiment, ! the puff volume, and ! the filter 
ventilation (i.e. fraction of air flow through filter vents) then 
!!,!∗ = !!,!!!(1− !!)                  (1) 
where !!,!∗  represents the undiluted smoke volume, and k is the machine smoking protocol for the ith 
sample (cigarette). For the ISO protocol !=35 mL and ! ranges from 0 to 1, for MDPH !=45 mL 
and ! is half the filter ventilation, and for the HCI protocol !=55 mL and !=0.  
The usefulness of the !∗ parameter is illustrated in Supplementary figure S1 in which nicotine 
concentrations from the various smoking machine experiments are plotted against !!,!∗ .[14] The 
graph shows strong correlation between undiluted smoke volume !∗ and nicotine concentration per 
cigarette (r2=0.93, p<0.01) with a linear regression intercept close to the origin. Similar co-linearity 
of !∗ over the major carcinogens under consideration provides a means of expressing smoke 
carcinogens as concentrations in a form independent of machine smoking protocol.  
!!,!,! = !!,!,!!"# !!,!∗                                       (2) 
where !!,!,!!"#  (µg/cigarette) is the mass per cigarette of the jth carcinogen in the ith product that has 
been machine-smoked using protocol k. !!,!,! is the carcinogen concentration in units of µg/mL in 
undiluted smoke. This transformation expresses tobacco smoke toxicants as concentrations in the 
product, in common with ECs. Furthermore the denominator V* is a good proxy for nicotine 
(Supplementary figure 1). HnB emissions are treated the same as tobacco smoke. Toxicants in EC 
vapours (!!,!!"#), usually reported as mass/volume concentrations, only need conversion to µg/mL, 
as appropriate.  
Aerosol cancer potency  
Environmental protection agencies assess toxicological, epidemiological and other data relevant to 
the long-term risks of inhaling chemicals.[15] Unit risk values for cancer have been published 
where data are deemed adequate.[16] The inhalation unit risk (!!) for the jth carcinogen is defined 
as the excess lifetime cancer risk from continuous inhalation exposure to 1 µg of the carcinogen per 
m3 of air and is expressed in (µg/m3)-1.[15] 
The cancer potency from the mixture of carcinogens in tobacco smoke may be estimated using an 
aggregate model that weights each inhalation unit risk by its concentration in undiluted smoke 
!!,!!"# = !!,!,!!!!! !!                                3 . 
Similarly, the cancer potency of EC vapour can be formulated as  
!!!"# = !!,!!"#!!!! !!                           4 . 
. 
!!"#  and !!"#  are aggregates of individual compound potencies and are measures of the 
carcinogenic potential of a given aerosol. The normalised ratio 
!!! = !! !!"#  (5) 
is the cancer potency of smoke or vapour relative to average tobacco smoke and is the 
dimensionless parameter used to discuss relative potency below. 
Modelling exposure and risk 
Metrics of exposure that reflect human use patterns are needed to translate potencies into risk 
estimates for each nicotine product.[17] Studies of smoking usually report the number of cigarettes 
per day. Analogous reports of EC vaping topographies include estimates of vapour volume inhaled 
per day. Vaping is associated with greater volumes than tobacco smoking, possibly resulting in 
greater relative risks than implicit in the potency spectrum.[17]  
The Lifetime Cancer Risk (!!!"#) for the ith cigarette based on daily smoke exposure (assuming HCI 
conditions) takes into account the mean daily cigarettes in stick units (!) and the daily breathing 
rate of air (!), typically 20m3, 
!!!"# = !!"#,!,!!"#!!!! !!!   !                     6 . 
The same procedure is applied to HnB tobacco sticks.  
For EC, the Lifetime Cancer Risk (!!!"#) for the ith product is the aerosol potency scaled by the 
average daily volume of vapour inhaled !!"#!"#, 
!!!"# = !!!"#  !!"#!"# !                               7 . 
 
The mean daily number of cigarettes smoked was 13 in 22 countries during 2008-14.[18] In 2016, 
the average daily consumption in the UK was 12 cigarettes whereas in the US in 2015 the 
comparable figure was 14. [19, 20] For this study, cigarettes per day were rounded to 15 reflecting 
the low daily smoking in these countries. The same number is applied to HnB modelling, consistent 
with exposure studies in Japan (average 10 sticks/day) and Poland (average 17).[21, 22] 
The average daily volume of EC vapour inhaled (!!"#!"#) has been reported as 29.7 L/day based on 
measurements using 22 subjects over a 24 hour period but this result is associated with considerable 
variability (standard deviation 29.6).[23] A daily volume of 30 L is used here for risk modelling 
while recognising the large uncertainty involved. It has also been estimated that about four times 
greater volume of vapour is inhaled than tobacco smoke and this is broadly consistent with the 
adopted values.[24] This volume falls within the range of daily nicotine inhaler use.[25]  
Data sources 
Eleven compounds commonly reported in tobacco smoke are classified by the International Agency 
for Research on Cancer (IARC) as human carcinogens (Type 1) and a further 7 as possible human 
carcinogens (Type 2B). The inhalation unit risks for 14 of these carcinogens were obtained from the 
Office of Environmental Health Hazard Assessment database (OEHHA, State of California, USA) 
supplemented with a recommended value for the carcinogenic nitrosamine NNK (Table 1).[26] 
Concentrations of several major carcinogens in cigarette smoke and in VNP vapour were obtained 
from studies of cigarettes[14, 27, 28] a prototype HnB device,[29] and EC products, ranging from 
early generation disposables though second-generation clearomisers and cartomisers to third 
generation mods and tanks.[7, 30-37] EC coil resistance and battery voltage were collated where 
reported. This compilation has many gaps where some carcinogens were not analysed. After 
removing duplicates across studies and omitting non-steady state emissions (where stated) the 
resulting dataset contained 93 analyses divided into three subsets.[34] The Goniewicz subset is the 
benchmark with 12 EC samples analysed for seven carcinogens including carbonyls, volatile 
organic compounds (VOCs), nitrosamines and metals.[7] The remaining 81 analyses include 
concentrations for some organic compounds (formaldehyde, acetaldehyde and occasionally VOCs) 
and thus yield minimum estimates of potency, of which 32 involved coil heating experiments 
applying multiple powers to the same liquid in the same device (variable power subset). The 
remainder (n=48) are termed the organics-only subset.    
Carcinogen emissions from an unheated nicotine inhaler represent a device accepted for medical 
use.[7] Ambient air is represented by a suite of analyses that establish a relatively uncontaminated 
reference baseline for studies of smoke and vapour exposure.[38] 
CARCINOGENS 
TOBACCO 
SMOKE 
n=309 
HEAT-NOT-BURN 
EMISSION 
n=44 
E-CIGARETTE 
VAPOUR 
n=44 
NICOTINE 
INHALER 
n=1 
Compound IARC type 
OEHHA  
unit risk Uj 
(µg/m3)-1 
Mean 
concentration  
Ej (µg/mL) 
Mean concentration 
Ej (µg/mL) 
Mean concentration in 1st 
& 2nd generation e-cigs  
Cj (µg/mL) 
Mean concentration  
Cj (µg/mL) 
Acetaldehyde  2B 2.7 x 10-6 2.55 x 10-0 3.33 x 10-1 4.41 x 10-3 1.05 x 10-4 
Formaldehyde 1 6.0 x 10-6 1.54 x 10-1 1.06 x 10-2 8.07 x 10-3 1.90 x 10-4 
Acrylonitrile 2B 2.9 x 10-4 4.59 x 10-2 2.96 x 10-4 NR NR 
Benzene 1 2.9 x 10-5 1.57 x 10-1 9.32 x 10-4 NR NR 
1,3-Butadiene 1 1.7 x 10-4 1.83 x 10-1 3.94 x 10-4 NR NR 
2-Amino-naphthalene 1 5.14 x 10-4 4.13 x 10-5 4.82 x 10-8 NR NR 
4-Amino-biphenyl 1 6.0 x 10-3 8.68 x 10-6 1.80 x 10-8 NR NR 
Benzo[a]pyrene 1 1.1 x 10-3 3.67 x 10-5 2.12 x 10-6 NR NR 
NNN 1 4.0 x 10-4 4.63 x 10-4 2.57 x 10-5 1.94 x 10-7 BDL 
NNK 1 4.0 x 10-4 2.88 x 10-4 1.64 x 10-5 8.39 x 10-7 BDL 
Cadmium 1 4.2 x 10-3 1.99 x 10-4 BDL 1.01 x 10-5 9.52 x 10-7 
Lead 2B 1.2 x 10-5 7.52 x 10-5 4.09 x 10-6 7.06 x 10-6 1.90 x 10-6 
Chromium 1 1.5 x 10-1 BDL BDL NR NR 
Nickel 2B 2.6 x 10-4 BDL BDL 6.98 x 10-6 1.90 x 10-6 
Arsenic 1 3.3 x 10-3 2.20 x 10-5 2.14 x 10-6 NR NR 
MEAN CANCER POTENCY RATIO (equation 5) 1.0 x 10-0 2.01 x 10-2 1.81 x 10-3 1.02 x 10-4 
MEAN LIFETIME CANCER 
RISK (equations 6 & 7) 
 consumption 15 cigarettes/day 15 sticks/day 30 L vapour/day 30 L vapour/day 
 risk 2.4 x 10-2 5.7 x 10-4 9.5 x 10-5 8.9 x 10-6 
 ratio to tobacco smoke 1.0 0.024 0.004 0.0004 
 ratio to nicotine inhaler 2697 64 10.7 1.0 
Table 1. Unit risks and average concentrations for IARC type 1 and 2 carcinogens measured in tobacco smoke and other forms of nicotine delivery. Average 
concentrations for e-cigarettes for 1st and 2nd generation devices only (where identifiable). See text for sources of data. Concentrations in bold type represent 
compounds that contribute more than 5% of the modelled potency for a particular form of delivery. Abbreviations: BDL Below Detection Limit, NR Not Reported, 
NNN N'-nitrosonornicotine, NNK 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. 
RESULTS 
Distribution of cancer potencies 
Cancer potencies were computed for the datasets using equations 3 & 4 following conversion into 
compatible units of concentrations (equations 1-2) and matched with unit risks for cancer. The 
calculation sequence is summarised in Table S1 (Supplementary file). Average concentrations, unit 
risks and cancer potencies for various nicotine products are given in Table 1 and the potencies of 
individual samples are graphically presented in figure 1. All results are normalised to the average 
value for tobacco smoke and plotting the results on a logarithmic axis creates a relative cancer 
potency spectrum for the various nicotine-bearing aerosols.  
Smoke collected under the ISO protocol and converted to undiluted smoke volume V* has 
essentially the same potency as that collected under HCI (figure 1). Without factoring for filter 
ventilation the ISO samples would be widely dispersed ranging down to much lower apparent 
cancer potencies for the most ventilated brands. HCI and ISO tobacco smoke have the same 
distributions after applying the V* conversion (figure 1) which indicates that raw undiluted tobacco 
smoke defines a narrow band on the potency spectrum regardless of protocol and defines the upper 
boundary of cancer potencies among common nicotine products in high income countries. 
Ambient air, essentially a non-hazardous aerosol, defines the lower end of the cancer potency 
spectrum, clustering around a carcinogenic potency of slightly less than 10-5 that of tobacco smoke. 
The potency of the nicotine inhaler is about 10-4 that of tobacco smoke (figure 1), with metals 
contributing more than 70% of its carcinogenic potency. 
The cancer potencies of EC are more difficult to define and are highly dispersed compared with 
cigarettes. The Goniewicz subset, which analyses the majority of anticipated carcinogens in EC 
vapour, clusters around ~10-3 of the potency of tobacco smoke (figure 1). The preponderance of 
potencies in the organics-only and variable power subsets also fall in this range although higher 
levels of carbonyls found in these two subsets extend the range as far as the potency of tobacco 
smoke.  
The cancer potencies of the HnB prototype device that heated various tobacco blends, lie between 
one and two orders of magnitude less than tobacco smoke but higher than the preponderance of EC 
emissions (figure 1). 
Lifetime cancer risk 
Equations 6 and 7 estimate the lifetime cancer risks from daily exposure (Table 1). The values for 
ECs in this table are based on a compilation of 1st and 2nd generation devices because most 3rd 
generation tanks and mods were used for variable voltage experiments. The average for EC includes 
the Goniewicz subset supplemented by carbonyl analyses from those members of the organic-only 
subset for which the device generation could be identified. The potency ratio relative to tobacco 
smoke for the average of these ECs is 1.8 x10-3 while HnB had an order of magnitude higher 
relative potency at 2.1 x 10-2. The excess cancer risk for a lifetime of smoking 15 cigarettes a day is 
2.4 x 10-2, 5.7 x 10-4 for inhaling 15 HnB sticks, 9.5 x10-5 for vaping 30 L from ECs at normal 
power, and 8.9 x10-6 for inhaling 30 L from the nicotine inhaler (Table 1). Compared with a 
nicotine inhaler the relative risks are 11 for EC, 64 for HnB and ~2700 for cigarettes, whereas 
compared with cigarettes the relative risks are 0.024 for HnB, 0.004 for EC and 0.0004 for the 
nicotine inhaler (Table 1). 
Ranking carcinogens 
The highest-ranking carcinogens in Table 1 for cigarettes are 1,3-butadiene and acrylonitrile, 
accounting for more than three-quarters of the cancer potency, whereas for HnB, acetaldehyde is 
the dominant carcinogen, which along with 1,3-butadiene accounts for almost three-quarters of the 
aerosol’s potency. For ECs, only the Goniewicz subset includes nitrosamines and metals as well as 
carbonyls and VOCs. The highest ranked carcinogens in this subset are cadmium and formaldehyde. 
Even very small levels of cadmium can have a major effect given its extremely high unit risk (Table 
1) but cadmium is not detected in all samples and in others it is present in concentrations very close 
to blank level.[7] The carbonyls formaldehyde and acetaldehyde account for over 95% of the 
contributions of organic compounds to cancer potencies in this EC subset. 
The role of carbonyls in the cancer potency of EC vapour 
Given the importance of the carbonyls as carcinogens in EC vapour the relationship between battery 
voltage and carbonyl generation is explored further in figure 2. Several studies have addressed this 
issue by measuring carbonyl concentrations under various experimental conditions.[31, 32, 34, 37, 
39] These were omitted from the modelling of potency and risk of Table 1 because they often 
involve applying voltages beyond the normal range of use. This figure shows that the partial cancer 
potencies attributable to both formaldehyde and acetaldehyde are highly variable. The Goniewicz 
subset and some other samples from both of the other subsets represent the lower range of potencies 
attributable to carbonyls. Other data indicate considerably higher potencies due to both carbonyls, 
sometimes approaching and, for formaldehyde, even exceeding the partial potencies of carbonyls in 
conventional tobacco smoke (figure 2).  Most of the high-potency data points in figure 2 were from 
studies investigating carbonyl formation by varying the atomiser coil heat within the same device 
while varying the power (watts) at the fluid-coil interface. Solid lines in figure 2 connect the various 
powers achieved in the same experiment with the direction of increasing power indicated by an 
arrow. The highest cancer potencies are commonly associated with coils subjected to the highest 
applied voltages in any particular experiment, however there is no consistent relationship between 
devices for carbonyl potency and the rate of heat energy transfer (watts) at the coil. It has been 
suggested that such high power operating conditions produce “dry puffs”, i.e. when the supply of e-
liquid to the heating coil is inadequate producing an aerosol which is unpleasant to inhale although 
an exclusive causal relationship between dry puffs and high aldehyde concentrations has been 
questioned.[40, 41] 
DISCUSSION  
Strengths and limitations of emissions modelling 
The accuracy of emissions modelling can be evaluated by comparing the lifetime risk model for 
tobacco smoking with epidemiological data for smoking-related mortality. An early application of 
this model to tobacco smoke predicted an excess risk of 1.6 x 10-2 for a daily consumption of 20 
cigarettes measured with the ISO protocol.[26] This differed from the estimated excess cancer risk 
of 7.9 x 10-2 derived from mortality data for smokers in the USA in 1995.[14] Applying the same 
model to the Centers for Disease Control (CDC) tobacco smoke dataset  measured with the HCI 
protocol weighted by current OEHHA unit risk values doubles the estimated risk to 3.3 x 10-2 
averaged over 48 cigarette products (standard deviation 3.5 x 10-3) for the same daily consumption 
rate. This closer agreement is largely due to the use of the HCI machine smoking protocol for 
emissions suggesting that these independent estimates reflect the same fundamental causes of 
mortality.  
Using emissions can under- and over-estimate risk Aggregation of risks for individual carcinogens 
assumes that each inhaled carcinogen is wholly absorbed and no account is taken of differential 
mechanisms and rates of clearance. Unit risks are upper bound toxicological estimates that may 
overestimate true potency.[42] If large volumes of carbonyls are generated by EC use under 
circumstances not normally tolerated by humans (e.g. “dry puffs”) then the apparent high risk levels 
may not be reached.[40]  
A simple aggregation does not account for enhancement by synergystic interactions between 
components (but there may also be antagonistic interactions). A few synergystic effects are well 
known, often between tobacco smoke and particles such as asbestos and silica but these are largely 
restricted to industrial exposure (although silica particles have been recognised in EC vapour).[43, 
44] Unit risk values are not available for all known carcinogens and are thus not involved in the 
aggregation leading to underestimation. Furthermore, only carcinogens formally classified by IARC 
are included. Although cigarette smoke has been thoroughly investigated for toxicants over several 
decades EC have not received the same level of scrutiny and some carcinogens are possibly yet to 
be identified, although these “missing carcinogens” would need to be present in high concentrations 
and/or have high unit risks to make a noticeable difference to EC potency and risk. Other sources of 
uncertainties are differences in unit risks between environmental protection authorities, and the 
assumption that risk is linearly proportional to dose with no threshold.  
Another limitation is the absence of carcinogen analyses in most published studies of EC vapours. 
Only the Goniewicz subset presents data for most of the relevant carcinogens and these indicate 
very important roles for metals (especially cadmium) and formaldehyde. The importance of 
cadmium as a carcinogen in vapour needs further investigation, as it has not been detected at 
hazardous levels in other studies of vapour.[44-46] Also missing from most studies are analyses of 
the nitrosamine carcinogens, notably (methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and N’-
nitrosonornicotine (NNN), although potencies calculated from the Goniewicz subset suggest these 
are minor contributors to the risk (Table 1). Indeed missing data for carcinogens at low 
concentrations or with low unit risks may have little or no significant effect on modelled potency 
and risk. Note that particle size effects have not been taken into account in this or previous chemical 
studies of this type but are potentially significant.[47, 48] 
VNP and cigarette emissions have been compared in this study using carcinogen concentrations 
whereas normalisation to unit nicotine levels is sometimes preferred as an estimate of human 
exposure.[49] Nicotine has an unprotonated (free-base) and two protonated forms, unprotonated 
nicotine being of greatest concern in terms of blood transfer. The fraction of total nicotine in free-
base form varies widely in both tobacco smoke and EC vapour largely as a function of pH.[50, 51]  
Whether free-base nicotine could be a useful proxy for exposure in tobacco-based aerosols requires 
further research as does the relationship between the concentrations of the various nicotine forms 
and exposure to toxicants in EC emissions.  
Biomarkers for 1,3-butadiene and acrylonitrile in urine samples from EC-only users indicate levels 
similar to nicotine replacement therapy users, in contrast to the high levels found in smokers.[10] 
Biomarkers for the same compounds declined rapidly in smokers switching to ECs at rates similar 
to abstinence from smoking over five days.[52] Neither compound is normally detectable in EC 
vapour yet both have been shown above to account collectively for more than three-quarters of the 
cancer potency of tobacco smoke.[53] This close correlation between reduced emissions in EC 
vapours and their associated biomarkers for two of the most important carcinogens in tobacco 
smoke supports the use of emissions in estimating potency and risk. 
Carbonyl generation 
The preponderance of EC analyses conducted at recommended voltages indicates relatively low 
risks of exposure related to carbonyls (figure 2, table 1), notwithstanding, additional carbonyl 
generation at higher powers has a major influence on cancer potency (figure 2). While factors such 
as the propylene glycol/glycerol balance and other e-liquid ingredients as well as puff number may 
influence aldehyde formation, overheating appears to dominate.[34, 54-56] Indeed, the connected 
arrows on figure 2 indicate that up to half the cancer potency range for ECs can be generated from 
the same liquid in a single device by varying only the power. This implies that the way a device is 
used might be more important than the device itself. The unpleasant sensory experience of a “dry 
puff” may mean that these laboratory-derived data points are replicated less frequently in normal 
human exposure than implied by the machine smoking data presented in figure 2.[40]  
Heat-not-Burn devices 
Data from experiments on one HnB device indicates cancer potencies and risks lower than tobacco 
smoke by more than one order of magnitude greater than the preponderance of ECs operating under 
normal conditions (Table 1). This finding is provisional as it is based on a single prototype design 
from a single manufacturer. 
Caveats 
Unit risk values (Table 1) indicate a potentially major role for metals even at low concentrations. 
ECs are typically metallic devices, not least the atomiser which is normally a metallic coil usually 
made of nichrome (NiCr alloy) or kanthal (FeCrAl alloy). Other metallic components can include 
electrical conductors, crimps, connectors, solder, cartridges and structural features of the device, 
many of which show some evidence of corrosion over time in pre-filled devices. Several papers 
document elevated levels of metals in liquids and occasionally the aerosol but no consistency is yet 
evident in emissions.[7, 44, 45, 57] The lack of metals data for samples other than the Goniewicz 
subset mean that some cancer potency values for ECs in this study may be underestimated. Even 
less is known about the speciation of metals in EC vapour despite the importance of different 
valence states and molecular speciation in tobacco smoke toxicity.[58, 59] More detailed study of 
metals, especially Ni, Cr and Pb and their speciation in a wider of range of products may lead to 
new perspectives on the cancer potential of metals in EC vapours.  
The presence of fine and nanosize particulates in EC vapour was recently demonstrated.[48] Given 
the greater surface area and potential reactivity of nanoparticles, if their presence in VNP vapours is 
confirmed as substantial then safety estimates for these products may require re-evaluation, 
especially in relation to cancer, respiratory and cardiovascular diseases including stroke.[60] 
The cancer potency of second hand vapour was not specifically addressed in this study. The few 
published experiments of secondhand vaping suggest low cancer potencies although none appeared 
to involve products that emitted relatively high levels of carbonyls in the mainstream vapour.[61, 
62]  
Implications for policy and practice 
The data imply a considerable range of cancer risks. Many EC emissions have cancer potencies 
within an order of magnitude of a nicotine inhaler, a product generally regarded as safe. 
Notwithstanding, some EC emissions tended towards much higher cancer potencies and risks, a few 
possibly approaching those of tobacco smoke. Indeed, the cancer potency of formaldehyde, the 
most important EC carcinogen, can exceed that of tobacco smoke especially in the highest power 
settings of some multi-power experiments but the full range of relative potency spans nearly 4 
orders of magnitude with the vast majority of potencies being much lower than combustible 
cigarettes. It is likely that 3rd-4th generation EC devices with adjustable coil power, are implicated in 
these higher risks. With regard to involuntary exposure, better understanding of potential effects of 
second-hand EC exposure is needed to determine if their use in indoor public spaces should be 
banned, as is currently the case in 25 countries.[63]  
The conclusions of this study refer only to the chemical risks of cancer and do not account for any 
other carcinogenic effects such as those attributable to small particle sizes. There is some evidence 
that the large differentials found here between the cancer potencies of most ECs and those of 
tobacco smoke may be less for other medical conditions involving the cardiovascular and 
respiratory systems.[37] Future research should address these gaps. 
The cancer potency calculation for VNPs was applied to a range of devices covering different 
generations purchased in different countries but no claim is made that these samples are 
representative of all products in the current marketplace. As the VNP market continues to expand 
and diversify a better understanding of the origins and aerosol transfer of carbonyls and metals is 
required to achieve EC emissions with consistently low carcinogenic potency. Such understanding 
may prompt calls for constraints on device design and e-liquid formulations but it is likely that 
significant reduction in cancer risk could also be achieved by effective advice to EC users on 
generic aspects of devices, coil selection and refill liquids as well as vaping behaviour and product 
manipulation.   
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Figure 1. Relative cancer potency modelled for common forms of nicotine delivery. 
Potency is the aggregate estimated using equations 3 & 4 and normalised to average 
tobacco smoke with cancer risk set to 1.0 (equation 5). Each circle or ellipse on the 
graph represents the emission from a single sample or experiment in the peer 
reviewed literature. In all emissions from 14 peer-reviewed studies are summarised in 
the diagram (see text for data sources). MS=Mainstream smoke. 
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Figure 2. Relative cancer potencies of formaldehyde and acetaldehyde in vapour from 
e-cigarettes compared with tobacco smoke, heat-not-burn devices, a nicotine inhaler 
and ambient air. Values are normalised to the mean potency of the same carcinogens 
in tobacco smoke. Data sources for e-cigarettes are identified with different symbols 
(see key for sources). The variable power subset includes all devices used in 
experiments to create vapour at more than one atomiser power (watts). Solid red lines 
connect the potencies of emissions for the same device run at different powers with 
arrows indicating the direction of increasing power. The lines show that the cancer 
potencies from the same device can vary by more than two orders of magnitude for 
both formaldehyde and acetaldehyde. 
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